B Dahlof

Summary

Country: Sweden

Publications

  1. ncbi Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    Bjorn Dahlof
    Sahlgrenska University Hospital Ostra, Gothenburg, Swede
    Lancet 359:995-1003. 2002
  2. ncbi Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond
    B Dahlof
    Goteborg University, Goteborg, Sweden
    J Renin Angiotensin Aldosterone Syst 1:S14-6. 2000
  3. ncbi The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group
    B Dahlof
    Ostra University Hospital, Goteborg, Sweden
    Am J Hypertens 10:705-13. 1997
  4. ncbi Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    B Dahlof
    Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 18:367-73. 2004
  5. ncbi Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Goteborg, Sweden
    Am J Hypertens 5:95-110. 1992
  6. ncbi Management of cardiovascular risk with RAS inhibitor/CCB combination therapy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 23:77-85. 2009
  7. ncbi Left ventricular hypertrophy and angiotensin II antagonists
    B Dahlof
    Clinical Experimental Research Laboratory, Sahlgrenska University Hospital, Ostra, Goteborg, Sweden
    Am J Hypertens 14:174-82. 2001
  8. ncbi Further evidence for low-dose combinations in patients with left ventricular hypertrophy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 19:S9-14. 2005

Detail Information

Publications8

  1. ncbi Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    Bjorn Dahlof
    Sahlgrenska University Hospital Ostra, Gothenburg, Swede
    Lancet 359:995-1003. 2002
    ..We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death...
  2. ncbi Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond
    B Dahlof
    Goteborg University, Goteborg, Sweden
    J Renin Angiotensin Aldosterone Syst 1:S14-6. 2000
    ..This drug may provide additional benefits in controlling the cardiovascular complications of hypertension. Results of large clinical trials with valsartan, such as VALUE, Val-HEFT, VALIANT and ABCD-2V, are eagerly awaited...
  3. ncbi The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group
    B Dahlof
    Ostra University Hospital, Goteborg, Sweden
    Am J Hypertens 10:705-13. 1997
    ..On April 30, 1997, when inclusion was stopped, 9,218 patients had been randomized...
  4. ncbi Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    B Dahlof
    Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 18:367-73. 2004
    ..5-year period. A population-wide prevention strategy of using losartan in patients with LVH and hypertension has the potential to have a major public health impact by reducing the morbidity and mortality of stroke in the EU...
  5. ncbi Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Goteborg, Sweden
    Am J Hypertens 5:95-110. 1992
    ..However, this theory and its possible prognostic implications need to be evaluated in controlled prospective trials...
  6. ncbi Management of cardiovascular risk with RAS inhibitor/CCB combination therapy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 23:77-85. 2009
    ..Meanwhile, such a combination offers effective, convenient, well-tolerated control of the most important modifiable risk factor for CVD...
  7. ncbi Left ventricular hypertrophy and angiotensin II antagonists
    B Dahlof
    Clinical Experimental Research Laboratory, Sahlgrenska University Hospital, Ostra, Goteborg, Sweden
    Am J Hypertens 14:174-82. 2001
    ..Published data include open-label and randomized studies with losartan treatment for left ventricular hypertrophy, with fewer studies investigating the effects of valsartan, irbesartan, and candesartan...
  8. ncbi Further evidence for low-dose combinations in patients with left ventricular hypertrophy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 19:S9-14. 2005
    ..This reduction cannot be entirely explained by the better efficacy of the low-dose combination on blood pressure reduction...